The market for neutropenia treatments worth 60 billion won a year is expected to fluctuate significantly. The copyright of the No. 1 and No. 2 items in the second-generation neutropenia treatment market has shifted in succession, and new drugs have joined the competition in six years, signaling a upheaval.

◆Boryung and Jeil will change the top 2 items in the market and announce competition

According to the pharmaceutical industry on the 20th, Boryung Pharmaceutical recently signed a co-promotion contract for Neulasta (Pegfilgrastim) with Kyowa Kirin Korea. Boryung Pharmaceutical will start selling Neurastar in earnest starting this year. GC Pharma's Neulapeg (Pegteograstim